Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 9 of 9

TitleReference numberPublishedLast updated
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemiaTA891
Ibrutinib for treating Waldenstrom's macroglobulinaemiaTA795
Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal)TA702
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal)TA703
Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal)TA608
Ibrutinib for treating relapsed or refractory mantle cell lymphomaTA502
Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal)TA452
Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal)TA437
Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutationTA429

Results per page

  1. 10
  2. 25
  3. 50
  4. All